Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Clinical Pharmacology and Therapeutics|October 1, 1984
Sources of interindividual variations in acetaminophen and antipyrine metabolismR M Nash, L Stein, M B Penno, et al.Journal of Clinical Pharmacology|September 1, 1993
Effects of pyrazinoylguanidine on the glucose-fatty acid cycle in normal subjects and patients with non-insulin-dependent diabetes mellitusE S Vesell, C E Chambers, G T Passananti, et al.Science (New York, N.Y.)|March 2, 1973
Hepatic drug metabolism in rats: impairment in a dirty environmentE S Vesell, C M Lang, W J White, et al.Pharmacology|January 11, 1992
Pharmacokinetics of pyrazinoyl-guanidine, 3-aminopyrazinoyl-guanidine and their corresponding pyrazinoic acid metabolites in humans and dogsG T Passananti, E S Vesell, E V Jeszenka, et al.Clinical Pharmacology and Therapeutics|September 1, 1980
Antipyrine metabolism during the menstrual cycleE F Riester, E J Pantuck, C B Pantuck, et al.Clinical Pharmacology and Therapeutics|April 1, 1985
High levels of methylxanthines in chocolate do not alter theobromine dispositionC A Shively, S M Tarka, M J Arnaud, et al.Journal of Clinical Pharmacology|December 1, 1994
Pyrazinoylguanidine downregulates the glucose fatty-acid cycle in hypertensive, hyperinsulinemic diabetic patientsE S Vesell, C E Chambers, T D Seaton, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 1989
On the antipyrine test in laboratory animals. Studies in the dog and monkeyF F Vickers, T A Bowman, B H Dvorchik, et al.Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|September 1, 1990
Comparative studies of the mutagenicity of urine from smokers and non-smokers on a controlled non-mutagenic dietD J Doolittle, C A Rahn, E Riccio, et al.Federation Proceedings|April 1, 1976
Environmental and genetic factors affecting the response of laboratory animals to drugsE S Vesell, C M Lang, W J White, et al.Pageof 3